Positions

Selected Publications

Academic Article

Year Title Altmetric
2010 Dynamics of the drosophila circadian clock: Theoretical anti-jitter network and controlled chaos.  PLoS ONE.  5. 2010
2010 Malignant astrocytomas: A system disease.  Archives of Neurology.  67:353-355. 2010
2009 Mathematical model of the Drosophila circadian clock: Loop regulation and transcriptional integration.  Biophysical Journal.  97:2399-2408. 2009

Research Overview

  • Mathematical Modeling
    Cancer Biology
    Dynamical Systems
    Network Theory

    • Principal Investigator On

  • Private Grant  awarded by Sanofi US Services Inc 2013 - 2017
  • Private Grant  awarded by NOVOCURE (ISRAEL) LTD 2013 - 2016
  • Private Grant  awarded by NOVOCURE, INC. 2014 - 2016
  • Minimal-Perturbation Dynamic Control of the Melanoma Gene Regulatory Network  awarded by UNIVERSITY OF ILLINOIS (CHICAGO) 2010 - 2015
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2012 - 2014
  • Private Grant  awarded by Sanofi US Services Inc 2010 - 2013
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2010 - 2013

    • Investigator On

  • NCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors) Collaborative Agreement  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • A Pilot Study of Voraxaze(glucarpidase) in Patients with Central Nervous System Lymphoma  awarded by Memorial Sloan-Kettering Cancer Center 2019 - 2024
  • Brain Tumor Trials Collaborative Agreement  awarded by NIH - National Institutes of Health/DHHS 2019 - 2024
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019 - 2024
  • Private Grant  awarded by GLOBAL COALITION FOR ADAPTIVE RESEARCH 2020 - 2023
  • Private Grant  awarded by AGIOS 2020 - 2022
  • Private Grant  awarded by BIOMIMETIX JV LLC 2019 - 2022
  • Private Grant  awarded by IN8BIO INC. 2020 - 2022
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2014 - 2021
  • Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients  awarded by Johns Hopkins University 2020 - 2021
  • Private Grant  awarded by SUMITOMO DIANIPPON PHARMA ONCOLOGY INC 2018 - 2021
  • Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients with High Grade Gliomas  awarded by Johns Hopkins University 2020 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2021
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS 2016 - 2021
  • A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination with Anti-PD-1 in Patients with Recurrent GBM  awarded by Johns Hopkins University 2016 - 2021
  • Individualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)  awarded by Dana-Farber Cancer Institute 2018 - 2021
  • Phase O/I Study of AMG 232 Concentrations in Brain Tissue in Patients with Recurrent Glioblastoma and of AMG 232 in Combination with Radiation in Patients with Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters  awarded by Johns Hopkins University 2020 - 2021
  • Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma  awarded by Johns Hopkins University 2018 - 2021
  • A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide  awarded by Johns Hopkins University 2018 - 2021
  • Single-arm, Open-label Phase II Efficacy Study of First-in-class HIF2-Alpha Inhibitor, PT2385, for Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University 2017 - 2021
  • Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL 101553 in Combination with Standard Radiation in Patients with MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma  awarded by Johns Hopkins University 2017 - 2021
  • Phase I/II Study of BGB-290 with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations  awarded by Johns Hopkins University 2020 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2021
  • A Phase II Study of Binimetinib in Combination with Encorafenib in Adults with Recurrent BRAF V600-Mutated High-Grade Astrocytoma or other Primary Brain Tumor  awarded by Johns Hopkins University 2020 - 2021
  • Individualized Screening Trial of Innovative Glioblastoma Therapy (Insight)  awarded by Dana-Farber Cancer Institute 2019 - 2020
  • Phase I Study of MK-1775 with Radiation and Temozolomide In Patients with Newly Diagnosed Glioblastoma and Evaluation of lntratumoral Drug Distribution in Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University 2013 - 2020
  • A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma  awarded by National Cancer Institute/NIH/DHHS 2017 - 2020
  • Private Grant  awarded by VASCULAR BIOGENICS LTD 2016 - 2020
  • Private Grant  awarded by STEMLINE THERAPEUTICS INC 2014 - 2019
  • Private Grant  awarded by NATIVIS, INC. 2015 - 2019
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Private Grant  awarded by ORBUS THERAPEUTICS, INC. 2016 - 2018
  • A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrent High-Grade Glioma Undergoing Standard. Repeated Temozolomide Treatment (TAU-2010-1)  awarded by Johns Hopkins University 2013 - 2018
  • Private Grant  awarded by ARCHER BIOSCIENCES 2013 - 2018
  • Private Grant  awarded by ABBVIE INC 2015 - 2018
  • Private Grant  awarded by ABBVIE INC 2017 - 2018
  • Phase II Study of TRC102 in Combination with Temozolomide for Recurrent Glioblastoma  awarded by Johns Hopkins University 2016 - 2018
  • Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma (ABTC 1401)  awarded by Johns Hopkins University 2015 - 2018
  • Private Grant  awarded by ABBVIE INC 2017 - 2018
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS 2015 - 2017
  • Contemporary Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2011 - 2017
  • Pilot Study of MLN0128 in Preoperative Recurrent Glioblastoma (GBM) Patients  awarded by Johns Hopkins University 2014 - 2016
  • Contemporary Therapeutics for Anaplastic Gliomas - Brain Tumor Tissue Core  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by ARCHER BIOSCIENCES 2014 - 2015
  • A Phase lb Study of Cediranib in Combination with Cilengitide in Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University 2010 - 2014
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2013 - 2014
  • ACRIN 6684: Phase II Assessment of Tumor Hypoxia in Glioblastoma Using FMISO with PET and MRI (R09-185)  awarded by American College of Radiology 2010 - 2014
  • Private Grant  awarded by EMD SERONO 2009 - 2013
  • Private Grant  awarded by EMD SERONO 2009 - 2013

    • Education And Training

  • Doctor of Philosophy in Mathematics, University of Illinois System : Chicago 2007
  • Doctor of Medicine, 1985
  • American University Beirut, Internship 1986
  • Duke University Medical Center, Residency 1990
  • University of Chicago Hospitals, Residency 1989
  • Memorial Sloan Kettering Cancer Center, Postdoctoral Fellowship 1993

    • Full Name

  • Hassan Fathallah-Shaykh